•	Application No.	Applicant(s)
	10/009,685	HAAHEIM, LARS REINHARDT
, Notice of Allowability	Examiner	Art Unit
·	Gailene R. Gabel	1641
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to October 31, 2007 and Interview Summary on November 20, 2007.		
2. The allowed claim(s) is/are 22, 24-29, 31-42, and 47-49; now renumbered as claims 1-7,9,12-17,10,8,18,19,11, and 20-22 respectively.		
3. Acknowledgment is made of a claim for foreign priority una) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submin INFORMAL PATENT APPLICATION (PTO-152) which give 5. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner' Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the sheet. Replacement sheet(s) should be labeled as such in the sheet.	e been received. e been received in Application No cuments have been received in this of this communication to file a reply MENT of this application. hitted. Note the attached EXAMINER es reason(s) why the oath or declara st be submitted. son's Patent Drawing Review (PTO- c. s Amendment / Comment or in the Comment or in the Comment or the drawing several services.	national stage application from the complying with the requirements I'S AMENDMENT or NOTICE OF ation is deficient. 1948) attached Office action of the front (not the back) of
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT .		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 5. ☐ Notice of Informal F 6. ☒ Interview Summary 	* *
 Information Disclosure Statements (PTO/SB/08), 	Paper No./Mail Da 7. ⊠ Examiner's Amendi	te <u>11/20/07</u> .
Paper No./Mail Date	_	ent of Reasons for Allowagce
of Biological Material	9. ☐ Other	Gailene R. Gabel 11/20/2007
		Primary Examiner Art Unit 1641

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Dean Fanelli on November 20, 2007.

2. The application has been amended as follows:

In claim 25, line 1 after "The method as claimed in", --claim-- has been inserted.

In claim 47, line 2 after "the amount of newly", "synthesize" has been deleted and --synthesized-- has been inserted therefor.

In claim 47, line 5, after "antibody in response to said", "antigens" has been deleted and --immunogen-- has been inserted therefor.

3. The following is an examiner's statement of reasons for allowance: The prior art of record fails to teach or fairly suggest lysing lymphocytes obtained from a whole blood sample to determine the presence of newly synthesized antibodies in the blood sample in response to immunogenic response, whereupon the lymphocytes are in acute phase synthesis; hence enabling the detection of on-going synthesis in the lymphocytic cells. Prior art teaches detecting immunoglobulin that is secreted from cells because it was

Application/Control Number: 10/009,685 Page 3

Art Unit: 1641

never found nor appreciated that functional or pre-glycosylation antibodies could be present within lymphocytes in any significant measurable amount.

4. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gailene R. Gabel whose telephone number is (571) 272-0820. The examiner can normally be reached on Monday, Tuesday, and Thursday, 8:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Gailene R. Gabel Primary Examiner Art Unit 1641

November 20, 2007